A smokeless tobacco product or medicinal nicotine product includes nicotine and camphor dissolved in a non-flavored oily carrier. Preferably, the camphor is present in a concentration ranging from about 600 ppm to about 1300 ppm. Also disclosed are methods of making such products.

Membranes are described that may include aligned carbon nanotubes coated with an inorganic support layer and a polymeric matrix. Methods of membrane fabrication are described that may include coating an aligned carbon nanotube array with an inorganic support layer followed by infiltration with a polymeric solvent or solution. The support carbon nanotube membrane may have improved performance for separations such as desalination, drug delivery, or pharmaceuticals.

Membranes are described that may include aligned carbon nanotubes coated with an inorganic support layer and a polymeric matrix. Methods of membrane fabrication are described that may include coating an aligned carbon nanotube array with an inorganic support layer followed by infiltration with a polymeric solvent or solution. The support carbon nanotube membrane may have improved performance for separations such as desalination, drug delivery, or pharmaceuticals.

A method of extracting natural products, such as cannabinoids, flavonoids and terpenes, from plant material such as a Cannabis genus of plant is disclosed. The method affords a quick and efficient extraction of natural products without further purification.

A method of extracting natural products, such as cannabinoids, flavonoids and terpenes, from plant material such as a Cannabis genus of plant is disclosed. The method affords a quick and efficient extraction of natural products without further purification.

The specification discloses compositions for use in the oral or nasal cavity comprising a biologically active agent, a matrix forming agent comprising alginate and suitable salts thereof, a filling agent and at least one antioxidant that is an effective complex binder. The compositions can further comprise additional excipients such as preservatives, taste or flavour enhancers, pH adjusters, plasticizers and sweeteners. The specification also discloses methods of producing the compositions.

The specification discloses compositions for use in the oral or nasal cavity comprising a biologically active agent, a matrix forming agent comprising alginate and suitable salts thereof, a filling agent and at least one antioxidant that is an effective complex binder. The compositions can further comprise additional excipients such as preservatives, taste or flavour enhancers, pH adjusters, plasticizers and sweeteners. The specification also discloses methods of producing the compositions.

An inhaler article includes a body extending along a longitudinal axis from a mouthpiece end to a distal end and a capsule cavity defined within the body. The capsule cavity has a length extending along the longitudinal axis. A mouthpiece air channel extends from the capsule cavity to the mouthpiece end. An end cap is disposed within the distal end and extends to the capsule cavity. The end cap includes an air channel extending from the end cap distal end to the end cap inner end. A capsule is disposed within the capsule cavity and has a capsule length. The capsule length is in a range from about 25% to about 99% of the cavity length, or about 50% to about 95% of the cavity length, or about 70% to about 90% of the cavity length, or from about 75% to about 85% of the cavity length, or about 80% of the cavity length.

An inhaler article includes a body extending along a longitudinal axis from a mouthpiece end to a distal end and a capsule cavity defined within the body. The capsule cavity has a length extending along the longitudinal axis. A mouthpiece air channel extends from the capsule cavity to the mouthpiece end. An end cap is disposed within the distal end and extends to the capsule cavity. The end cap includes an air channel extending from the end cap distal end to the end cap inner end. A capsule is disposed within the capsule cavity and has a capsule length. The capsule length is in a range from about 25% to about 99% of the cavity length, or about 50% to about 95% of the cavity length, or about 70% to about 90% of the cavity length, or from about 75% to about 85% of the cavity length, or about 80% of the cavity length.

The present invention includes compositions and methods for treating certain conditions such as dry eye or dry mouth with a comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is provided in an amount sufficient to treat dry eye or dry mouth.